Johnson & Johnson (JNJ)vsQuanterix Corp (QTRX)
JNJ
Johnson & Johnson
$229.85
+1.10%
HEALTHCARE · Cap: $547.28B
QTRX
Quanterix Corp
$3.13
+2.62%
HEALTHCARE · Cap: $157.20M
Smart Verdict
WallStSmart Research — data-driven comparison
Johnson & Johnson generates 69277% more annual revenue ($96.36B vs $138.90M). JNJ leads profitability with a 21.8% profit margin vs -77.1%. JNJ earns a higher WallStSmart Score of 59/100 (C).
JNJ
Buy59
out of 100
Grade: C
QTRX
Hold42
out of 100
Grade: D
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-43.5%
Fair Value
$160.13
Current Price
$229.85
$69.72 premium
Margin of Safety
+83.2%
Fair Value
$34.95
Current Price
$3.13
$31.82 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 26 in profit
Keeps 22 of every $100 in revenue as profit
Strong operational efficiency at 27.4%
Generating 1.5B in free cash flow
Reasonable price relative to book value
Conservative balance sheet, low leverage
Revenue surging 24.7% year-over-year
Areas to Watch
Moderate valuation
Expensive relative to growth rate
Earnings declined 52.9%
0.0% earnings growth
Distress zone — elevated risk
Smaller company, higher risk/reward
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : JNJ
The strongest argument for JNJ centers on Market Cap, Return on Equity, Profit Margin. Profitability is solid with margins at 21.8% and operating margin at 27.4%.
Bull Case : QTRX
The strongest argument for QTRX centers on Price/Book, Debt/Equity, Revenue Growth. Revenue growth of 24.7% demonstrates continued momentum.
Bear Case : JNJ
The primary concerns for JNJ are P/E Ratio, PEG Ratio, EPS Growth.
Bear Case : QTRX
The primary concerns for QTRX are EPS Growth, Altman Z-Score, Market Cap.
Key Dynamics to Monitor
JNJ profiles as a mature stock while QTRX is a growth play — different risk/reward profiles.
QTRX carries more volatility with a beta of 1.32 — expect wider price swings.
QTRX is growing revenue faster at 24.7% — sustainability is the question.
JNJ generates stronger free cash flow (1.5B), providing more financial flexibility.
Bottom Line
JNJ scores higher overall (59/100 vs 42/100), backed by strong 21.8% margins. QTRX offers better value entry with a 83.2% margin of safety. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Johnson & Johnson
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Johnson & Johnson (J&J) is an American multinational corporation founded in 1886 that develops medical devices, pharmaceuticals, and consumer packaged goods. Its common stock is a component of the Dow Jones Industrial Average and the company is ranked No. 36 on the 2021 Fortune 500 list of the largest United States corporations by total revenue. Johnson & Johnson is one of the world's most valuable companies, and is one of only two U.S.-based companies that has a prime credit rating of AAA, higher than that of the United States government.
Visit Website →Quanterix Corp
HEALTHCARE · MEDICAL DEVICES · USA
Quanterix Corporation, a life sciences company, develops and markets digital immunoassay platforms that advance precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the regions from Asia Pacific. The company is headquartered in Billerica, Massachusetts.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?